Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.

• Phase: Phase 2

Details

• Lead Sponsor: Assaf-Harofeh Medical Center
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Subjects included if they were > 5 years old and suffered from intractable allergic conjunctivitis

Exclusion Criteria:

• pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides